Q-omics provides the consensus-scored TM2D1 profile across patient tissues and cancer cell-line models. TM2D1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, TM2D1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, TM2D1 RNA expression shows 20,253 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight CESC, HNSC, and ACC as cancer lineages where TM2D1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TM2D1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TM2D1 survival associations across molecular data types. TM2D1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TM2D1 RNA expression–survival associations across cancer types. High TM2D1 expression shows unfavorable associations in CESC, LIHC, ACC, LGG, KICH and SCLC. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for TM2D1 RNA expression.
This table summarizes TM2D1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TM2D1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TM2D1 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, BLCA and CHOL. The HNSC box plot shows higher TM2D1 RNA expression in tumor versus normal tissue (log2 FC = +0.472, t-test p < 0.001).
This table shows molecular features associated with TM2D1 in patient tissues and cancer cell lines. In patient samples, TM2D1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TM2D1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
